Abstract
<h3>To the Editor. —</h3> We read the article by Jolson et al<sup>1</sup>with interest, and we are concerned over the lack of objective, balanced information presented. We are aware of at least two published clinical trials<sup>2,3</sup>that did not validate the potential warfarin-fluoroquinolone interaction. The information provided by Jolson et al, as well as the published literature that has generated interest and concern about this potential interaction, has been derived from individual case reports. One cannot evaluate the predictability of an interaction from case reports alone, without appropriate clinical trials to support the interaction. Jolson et al state that the five patients had steady-state baseline prothrombin time (PT) ratios between 1.5 and 2 times the control ratio. They failed to mention their criteria for determining steady state. Additionally, reporting PT ratios rather than international normalized ratios (INRs) makes it difficult for the reader to judge steady-state criteria or
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
